Overview

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

Status:
Completed
Trial end date:
2020-11-03
Target enrollment:
Participant gender:
Summary
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bosnalijek D.D